Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
复制标题
1997 年至 2000 年,全球范围内,艾滋病毒暴露后使用奈韦拉平治疗方案进行暴露后预防的严重不良事件。
DOI:
--
复制
发表时间:
2001
期刊:
影响因子:
--
通讯作者:
S. Kukich
中科院分区:
文献类型:
--
作者:
S. Kukich
In September 2000, two instances of life-threatening hepatotoxicity were reported in health-care workers taking nevirapine (NVP) for postexposure prophylaxis (PEP) after occupational human immunodeficiency virus (HIV) exposure. In one case, a 43-year-old female health-care worker required liver transplantation after developing fulminant hepatitis and end-stage hepatic failure while taking NVP, zidovudine, and lamivudine as PEP following a needlestick injury (1). In the second case, a 38-year-old male physician was hospitalized with life-threatening fulminant hepatitis while taking NVP, zidovudine, and lamivudine as PEP following a mucous membrane exposure. To characterize NVP-associated PEP toxicity, CDC and the Food and Drug Administration (FDA) reviewed MedWatch reports of serious adverse events in persons taking NVP for PEP received by FDA (Figure 1). This report summarizes the results of that analysis and indicates that healthy persons taking abbreviated 4-week NVP regimens for PEP are at risk for serious adverse events. Clinicians should use recommended PEP guidelines and dosing instructions to reduce the risk for serious adverse events.
DOI:
10.1097/00002030-199603000-00006
发表时间:
1996
期刊:
AIDS (London, England)
影响因子:
--
作者:
Rodriguez,EM;Mofenson,LM;Chang,BH;Rich,KC;Fowler,MG;Smeriglio,V;Landesman,S;Fox,HE;Diaz,C;Green,K;Hanson,IC
通讯作者:
Hanson,IC